This pilot study explores an innovative mRNA-based vaccination approach targeting melanoma-associated antigens, which could position the University Hospital Tuebingen as a leader in personalized cancer immunotherapy. The study's completion and the focus on both fixed combinations and individualized antigen selection may provide valuable insights into patient-specific responses, potentially enhancing the therapeutic landscape for advanced melanoma. Given the increasing interest in mRNA technologies, particularly following the success of COVID-19 vaccines, this study could attract attention from biopharmaceutical companies seeking to expand their oncology portfolios. The competitive landscape includes established immunotherapies such as checkpoint inhibitors, necessitating a clear demonstration of efficacy and safety to carve out a market niche.